TR201820102T4 - Fabri hastalığı gen tedavisi. - Google Patents

Fabri hastalığı gen tedavisi. Download PDF

Info

Publication number
TR201820102T4
TR201820102T4 TR2018/20102T TR201820102T TR201820102T4 TR 201820102 T4 TR201820102 T4 TR 201820102T4 TR 2018/20102 T TR2018/20102 T TR 2018/20102T TR 201820102 T TR201820102 T TR 201820102T TR 201820102 T4 TR201820102 T4 TR 201820102T4
Authority
TR
Turkey
Prior art keywords
galactosidase
vector
mice
fabri
levels
Prior art date
Application number
TR2018/20102T
Other languages
English (en)
Turkish (tr)
Inventor
Nathwani Amit
Raj Deepak
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of TR201820102T4 publication Critical patent/TR201820102T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TR2018/20102T 2015-05-11 2016-05-10 Fabri hastalığı gen tedavisi. TR201820102T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1508025.2A GB201508025D0 (en) 2015-05-11 2015-05-11 Fabry disease gene therapy

Publications (1)

Publication Number Publication Date
TR201820102T4 true TR201820102T4 (tr) 2019-01-21

Family

ID=53489437

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/20102T TR201820102T4 (tr) 2015-05-11 2016-05-10 Fabri hastalığı gen tedavisi.

Country Status (17)

Country Link
US (2) US11103596B2 (enExample)
EP (2) EP3470088A1 (enExample)
JP (1) JP6688812B2 (enExample)
KR (1) KR20180012772A (enExample)
CN (1) CN107980063B (enExample)
AU (1) AU2016261453C1 (enExample)
CA (1) CA2985935C (enExample)
DK (1) DK3244931T3 (enExample)
ES (1) ES2703814T3 (enExample)
GB (1) GB201508025D0 (enExample)
HR (1) HRP20190165T1 (enExample)
LT (1) LT3244931T (enExample)
PL (1) PL3244931T3 (enExample)
PT (1) PT3244931T (enExample)
TR (1) TR201820102T4 (enExample)
TW (1) TW201706412A (enExample)
WO (1) WO2016181122A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
CA2996420A1 (en) 2015-09-28 2017-04-06 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
EP3458590B9 (en) 2016-05-18 2021-08-18 ModernaTX, Inc. Polynucleotides encoding -galactosidase a for the treatment of fabry disease
SG11202009451VA (en) 2018-04-03 2020-10-29 Stridebio Inc Antibody-evading virus vectors
CA3094465A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
WO2019210187A1 (en) * 2018-04-26 2019-10-31 The University Of North Carolina At Chapel Hill Methods and compositions for treatment of hemophilia
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
MX2021001901A (es) * 2018-08-20 2021-05-27 Ucl Business Ltd Nucleotidos de codificacion del factor ix.
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
WO2020077114A2 (en) 2018-10-10 2020-04-16 Amicus Therapeutics, Inc. Disulfide bond stabilized polypeptide compositions and methods of use
SG11202110146VA (en) 2019-03-21 2021-10-28 Stridebio Inc Recombinant adeno-associated virus vectors
CN114423428A (zh) * 2019-08-07 2022-04-29 阿米库斯治疗学公司 治疗在gla基因中具有突变的患者的法布里病的方法
EP4045525A1 (en) 2019-10-17 2022-08-24 Stridebio, Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
US20220387558A1 (en) 2019-11-01 2022-12-08 Freeline Therapeutics Limited Transcription regulatory elements
WO2021183895A1 (en) * 2020-03-13 2021-09-16 Biomarin Pharmaceutical Inc. Treatment of fabry disease with aav gene therapy vectors
TWI769795B (zh) * 2020-04-27 2022-07-01 美商４Ｄ分子療法公司 密碼子優化的ｇｌａ基因及其用途
IL297756A (en) * 2020-04-29 2022-12-01 Saliogen Therapeutics Inc Compositions and methods for treatment of familial hypercholesterolemia and elevated low-density lipoprotein cholesterol
TW202227632A (zh) 2020-08-19 2022-07-16 美商史崔德生物公司 用於治療雷特症候群之腺相關病毒載體
CN114507692B (zh) * 2020-11-16 2024-07-12 舒泰神（北京）生物制药股份有限公司 用于治疗法布里病的腺相关病毒载体及其用途
WO2022100748A1 (en) * 2020-11-16 2022-05-19 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Recombinant adeno-associated viruses with enhanced liver tropism and uses thereof
EP4326290A4 (en) * 2021-04-20 2025-05-14 Walking Fish Therapeutics, Inc. PRODUCTION OF B-CELL-BASED PROTEIN FACTORIES FOR THE TREATMENT OF SERIOUS DISEASES
GB202205514D0 (en) 2022-04-13 2022-05-25 Freeline Therapeutics Ltd Mechanical lysis
CN114672501B (zh) * 2022-05-27 2022-08-23 珠海丽凡达生物技术有限公司 一种mRNA、药物组合物及其应用
WO2024044697A2 (en) * 2022-08-24 2024-02-29 Walking Fish Therapeutics, Inc. Compositions and methods for treatment of fabry disease
WO2024217422A1 (en) * 2023-04-17 2024-10-24 Exegenesis Bio Co. Compositions and methods for gene therapies
CN116622750B (zh) * 2023-06-01 2024-05-31 上海勉亦生物科技有限公司 优化的人法布里转基因表达盒及其用途
CN116656704B (zh) * 2023-06-01 2024-11-05 华东理工大学 用于治疗法布里病的转基因表达盒
WO2025087695A1 (en) 2023-10-23 2025-05-01 Ascend Advanced Therapies Ltd Method for producing recombinant adeno-associated virus particles

Family Cites Families (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846968B1 (en) 1988-02-26 2005-01-25 Large Scale Biology Corporation Production of lysosomal enzymes in plants by transient expression
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
EP0832266A4 (en) 1995-06-07 2000-06-28 Univ Yale ORAL ADMINISTRATION OF VECTORS DERIVED FROM THE ADENO ASSOCIATED VIRUS
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
CA2265464C (en) * 1996-09-13 2007-06-26 Transkaryotic Therapies, Inc. Therapy for .alpha.-galactosidase a deficiency
AU762400B2 (en) 1996-09-13 2003-06-26 Shire Human Genetic Therapies, Inc. Therapy for alpha-galactosidase a deficiency
US20020082224A1 (en) 1997-01-14 2002-06-27 Douglas J. Jolly Non-immunogenic prodrugs and selectable markers for use in gene therapy
GB9708526D0 (en) 1997-04-25 1997-06-18 Royal Free Hosp School Med Eukaryotic gene expression cassette and uses thereof
US6210666B1 (en) 1997-10-21 2001-04-03 Orphan Medical, Inc. Truncated α-galactosidase A to treat fabry disease
EP1658857A1 (en) 1997-10-29 2006-05-24 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
IL135578A0 (en) 1997-10-29 2001-05-20 Genzyme Corp Compositions and methods for treating lysosomal storage disease
US6607879B1 (en) 1998-02-09 2003-08-19 Incyte Corporation Compositions for the detection of blood cell and immunological response gene expression
WO1999041399A1 (en) 1998-02-17 1999-08-19 Genzyme Corporation Methods for purified aav vector production
WO1999057296A1 (en) 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US20020065236A1 (en) 1998-09-09 2002-05-30 Yew Nelson S. CpG reduced plasmids and viral vectors
US20090017533A1 (en) 1998-09-29 2009-01-15 Shire Human Genetic Therapies, Inc., A Delaware Corporation Optimized messenger rna
AU2004242550B2 (en) 1999-03-11 2008-04-03 Shire Human Genetic Therapies, Inc. Treatment of alpha-Galactosidase A deficiency
GB9909066D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
WO2002064799A2 (en) 1999-09-28 2002-08-22 Transkaryotic Therapies, Inc. Optimized messenger rna
EP2275559A3 (en) 1999-09-28 2011-03-23 Shire Human Genetic Therapies, Inc. Optimized messenger RNA
DE60038045T2 (de) 1999-11-05 2009-02-05 Jena Bioscience Gmbh Nicht-pathogenes kinetoplastid protein-expressionssystem
WO2001036620A2 (en) 1999-11-16 2001-05-25 Genzyme Corporation Vectors and transgenies with regulatory elements for gene delivery to the liver
WO2001049830A2 (en) 1999-12-30 2001-07-12 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
WO2001060377A2 (en) 2000-02-17 2001-08-23 Genzyme Corporation Methods for treatment of lysosomal storage diseases using biphosphonates
JP2003533437A (ja) 2000-02-17 2003-11-11 ジェンザイム・コーポレイション 遺伝子デリバリーのための門戸としての肺の遺伝的修飾
US20020081654A1 (en) 2000-04-07 2002-06-27 Sandrin Mauro Sergio Targeting hydrolase enzymes
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20020014242A1 (en) 2000-07-31 2002-02-07 Abraham Scaria Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
US6667174B2 (en) 2000-09-18 2003-12-23 Genzyme Corporation Expression vectors containing hybrid ubiquitin promoters
EP1624067A3 (en) 2000-09-18 2006-03-15 Genzyme Corporation Expression vectors containing hybrid ubiquitin promoters
CA2854685A1 (en) 2000-10-11 2002-08-22 Richard F Selden Optimized messenger rna
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
JP2004535801A (ja) 2001-05-24 2004-12-02 ジェンザイム コーポレイション 筋特異的発現ベクター
JP4742191B2 (ja) 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
US7063962B2 (en) 2001-07-20 2006-06-20 Novozymes A/S DNA sequences for regulating transcription
US6749851B2 (en) 2001-08-31 2004-06-15 Clearant, Inc. Methods for sterilizing preparations of digestive enzymes
US6783968B2 (en) 2001-09-24 2004-08-31 Clearant, Inc. Methods for sterilizing preparations of glycosidases
US20030064000A1 (en) 2001-09-24 2003-04-03 Wilson Burgess Methods of sterilizing biological mixtures using stabilizer mixtures
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
EP1336411A1 (en) 2002-02-14 2003-08-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Compositions and methods for improving enzyme replacement therapy of lysosomal storage diseases
WO2003072035A2 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
BR122017016940B8 (pt) 2002-04-25 2021-07-27 Transkaryotic Therapies Inc método para preparação de uma composição farmacêutica compreendendo alfa-galactosidase a
US20030225260A1 (en) 2002-04-30 2003-12-04 Snyder Richard O. Production of recombinant AAV virions
EP1521523A4 (en) 2002-05-20 2006-04-19 Univ Texas METHODS AND COMPOSITIONS FOR DELIVERING NUCLEIC ACID ENZYMES AND MOLECULES IN BRAIN, BONE, AND OTHER FABRICS
US20030224477A1 (en) 2002-05-31 2003-12-04 Heartlein Michael W. Optimized promoter constructs
WO2003101202A1 (en) 2002-05-31 2003-12-11 Osiris Therapeutics, Inc. Intraperitoneal delivery of genetically engineered mesenchymal stem cells
EP1578367A4 (en) 2002-11-01 2012-05-02 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
US20070048301A1 (en) 2002-11-26 2007-03-01 Bodary-Winter Sarah C Compositions and methods for the treatment of immune related diseases
ES2371913T3 (es) 2003-01-22 2012-01-11 Duke University Constructos mejorados para expresar polipéptidos lisosomales.
CN1756558B (zh) 2003-01-31 2012-04-25 纽约大学西奈山医学院 酶和酶的活性部位特异性陪伴分子的组合
US7446098B2 (en) 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
CN1791679A (zh) 2003-03-19 2006-06-21 伊索格尼斯股份有限公司 基于CD8α链的具有降低的免疫原性的基因治疗载体
US20100196345A1 (en) 2003-04-27 2010-08-05 Protalix Production of high mannose proteins in plant culture
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
EP1620133B1 (en) 2003-05-01 2015-12-09 Genzyme Corporation Gene therapy for neurometabolic disorders
JP2006525371A (ja) 2003-05-05 2006-11-09 ジェンザイム コーポレイション 免疫応答を減少させる方法
CN101942442B (zh) 2003-06-24 2013-10-09 建新公司 新的β-肌动蛋白和RPS21启动子及其应用
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1694345A1 (en) 2003-12-04 2006-08-30 Regents Of The University Of Minnesota Compositions and methods for the treatment of lysosomal storage disorders
US20060029656A1 (en) 2004-02-03 2006-02-09 Biodelivery Sciences International, Inc. Replacement enzyme cochleates
US20080014188A1 (en) 2004-02-06 2008-01-17 Zankel Todd C Manufacture of Highly Phosphorylated Lysosomal Enzymes and Uses Thereof
US20050208090A1 (en) 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
NZ555830A (en) 2004-12-15 2009-01-31 Univ North Carolina Chimeric vectors
PL2420256T3 (pl) 2005-05-02 2016-12-30 Terapia genowa dla zaburzeń neurometabolicznych
US8500720B2 (en) 2005-05-09 2013-08-06 Medtronic, Inc Method and apparatus for treatment of cardiac disorders
CA2615218A1 (en) 2005-07-18 2007-01-25 Protalix Ltd. Mucosal or enteral administration of biologically active macromolecules
EP1945269A4 (en) 2005-10-31 2010-02-17 Zymequest Inc NEW A-GALACTOSIDASES
TWI500765B (zh) 2005-11-18 2015-09-21 Tokyo Metropolitan Inst Medical Science 轉換基質特異性之新穎高機能酵素
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
US7867484B2 (en) 2006-01-27 2011-01-11 University Of North Carolina At Chapel Hill Heparin and heparan sulfate binding chimeric vectors
SI1986661T1 (sl) 2006-02-08 2018-12-31 Genzyme Corporation Genska terapija za Niemann-Pickovo bolezen tipa A
HUE040490T2 (hu) 2006-02-09 2019-03-28 Genzyme Corp Lassú intraventrikuláris szállítás
AU2007253900A1 (en) 2006-05-16 2007-11-29 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for fabry disease
US20100144008A1 (en) 2006-12-21 2010-06-10 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of fabry disease
HRP20130744T1 (hr) 2007-01-18 2013-10-11 Genzyme Corporation Oligosaharidi koji sadrže aminooksi-skupinu i njezine konjugate
CA2584494A1 (en) 2007-03-27 2008-09-27 Jeffrey A. Medin Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
JP2010523578A (ja) 2007-03-30 2010-07-15 アミカス セラピューティックス インコーポレイテッド 薬理シャペロンを用いるファブリー病の治療方法
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
MX2009011473A (es) 2007-04-26 2010-01-18 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
EP3252161B1 (en) 2007-06-06 2021-11-17 Genzyme Corporation Gene therapy for lysosomal storage diseases
WO2009032171A1 (en) 2007-08-29 2009-03-12 Shire Human Genetic Therapies, Inc. Subcutaneous administration of alpha-galatosidase a
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
EP2252288A1 (en) 2007-11-21 2010-11-24 Summit Corporation Plc Treatment of protein folding disorders
EP2242840B1 (en) 2008-01-29 2019-07-24 Applied Genetic Technologies Corporation Recombinant adeno-associated virus production using bhk cells in suspension
LT3470077T (lt) 2008-02-12 2021-02-25 Amicus Therapeutics, Inc. Atsako į ligų gydymą farmakologiniu šaperonu prognozavimo būdas
WO2009114942A1 (en) * 2008-03-20 2009-09-24 University Health Network Thymidylate kinase fusions and uses thereof
WO2009137006A2 (en) 2008-04-30 2009-11-12 The University Of North Carolina At Chapel Hill Directed evolution and in vivo panning of virus vectors
ES2385735T3 (es) 2008-06-26 2012-07-31 Orphazyme Aps Uso de Hsp70 como regulador de la actividad enzimática
US20110237538A1 (en) 2008-08-06 2011-09-29 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
EP2465542B1 (en) 2008-12-16 2015-01-21 Genzyme Corporation Oligosaccharide-protein conjugates
ES2634118T3 (es) 2009-02-11 2017-09-26 The University Of North Carolina At Chapel Hill Vectores de virus modificados y métodos para fabricar y utilizar los mismos
GB0911870D0 (en) 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
WO2011019980A1 (en) 2009-08-14 2011-02-17 University Of Miami Novel role of alpha-galactosidase activity as a biomarker in kidney disease
WO2011039634A2 (en) 2009-09-29 2011-04-07 Universiteit Gent Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
JP2013506697A (ja) 2009-10-06 2013-02-28 アンジオケム インコーポレーテッド 治療薬を輸送するための組成物と方法
DK2493487T3 (en) 2009-10-27 2016-12-05 Erytech Pharma Composition for induction of specific immunological tolerance
WO2011057243A2 (en) 2009-11-09 2011-05-12 University Of Central Florida Research Foundation, Inc. Administration of plant expressed oral tolerance agents
WO2011061736A1 (en) 2009-11-17 2011-05-26 Protalix Ltd. Alkaline alpha galactosidase for the treatment of fabry disease
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
MY160542A (en) 2009-11-27 2017-03-15 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
WO2011088081A1 (en) 2010-01-12 2011-07-21 The University Of North Carolina At Chapel Hill Restrictive inverted terminal repeats for viral vectors
PL2865751T3 (pl) 2010-03-02 2017-03-31 Protalix Ltd Stabilizowana alfa-galaktozydaza i jej zastosowania
JP2013527753A (ja) 2010-03-23 2013-07-04 イントレキソン コーポレーション 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用
WO2011139379A2 (en) 2010-05-06 2011-11-10 Duke University A method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities
IL291554B2 (en) 2010-06-25 2024-02-01 Shire Human Genetic Therapies Administering therapeutic agents to the central nervous system
WO2012022777A1 (en) 2010-08-19 2012-02-23 Novozymes A/S Induced sporulation screening method
KR101983572B1 (ko) 2010-09-29 2019-05-29 옥시레인 유케이 리미티드 만노스-1-포스포-6-만노스 결합의 캡핑제거 및 인산화 n-글리칸의 탈만노실이 가능한 만노시다제 및 당단백질의 활용을 통한 포유류 세포의 촉진방법
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
WO2012098537A1 (en) 2011-01-20 2012-07-26 Protalix Ltd. Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
WO2012125402A2 (en) * 2011-03-11 2012-09-20 Amicus Therapeutics, Inc. Dosing regimens for the treatment of fabry disease
ES2745470T3 (es) 2011-03-31 2020-03-02 Univ Iowa Res Found Partícula de AAV2 que comprende una proteína de la cápside de AAV2 y un vector que comprende un ácido nucleico que codifica una tripeptidilo peptidasa 1 (TPP1) para el tratamiento de lipofuscinosis ceroide infantil tardía (LINCL) en un mamífero no roedor mediante inyección intraventricular o administración icv
US20120283290A1 (en) 2011-05-06 2012-11-08 Amicus Therapeutics Inc. Quantitation of gl3 in urine
CN103906527B (zh) 2011-06-08 2020-07-10 川斯勒佰尔公司 Mrna递送的脂质纳米颗粒组合物和方法
US20150258081A1 (en) 2011-12-22 2015-09-17 Centogene Ip Gmbh Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
CN104428009A (zh) 2012-02-07 2015-03-18 全球生物疗法美国有限公司 核酸输送的区室化方法及其组合物和应用
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
BR112014024131A2 (pt) 2012-03-29 2017-07-25 Shire Human Genetic Therapies lipídios catiônicos ionizáveis
CA2868391A1 (en) 2012-04-02 2013-10-10 Stephane Bancel Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9957495B2 (en) 2012-04-18 2018-05-01 Vib Vzw Means and methods for generating improved proteins
CA2874316A1 (en) 2012-05-03 2013-11-07 Indiana University Research And Technology Corporation Hydrodynamic methods for delivering fluids to kidney tissues and related materials and methods
EP2854834A4 (en) 2012-05-30 2016-05-18 Biostrategies LC PLANT LENSES AS CARRIER CORRESPONDING AGENTS IN ANIMAL AND HUMAN CELLS
US10648001B2 (en) 2012-07-11 2020-05-12 Sangamo Therapeutics, Inc. Method of treating mucopolysaccharidosis type I or II
ES2697912T3 (es) 2012-07-11 2019-01-29 Sangamo Therapeutics Inc Métodos y composiciones para el tratamiento de enfermedades monogénicas
WO2014014938A1 (en) 2012-07-17 2014-01-23 Amicus Therapeutics, Inc. Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
GB201213117D0 (en) 2012-07-24 2012-09-05 Ucl Business Plc Transgene expression
WO2014017915A2 (en) 2012-07-27 2014-01-30 Universiteit Utrecht Holding B.V. Urea and guanidinium derivatives of iminosugars
AU2013296557B2 (en) 2012-07-31 2019-04-18 Bioasis Technologies Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
US10138474B2 (en) 2012-08-17 2018-11-27 Research Foundation Of The City University Of New York Scavenger receptor uptake for fabry disease enzyme replacement therapy
ES2968649T3 (es) 2012-12-07 2024-05-13 Translate Bio Inc Nanopartículas lipídicas para la administración de ARNm en los pulmones
WO2014120900A1 (en) 2013-01-31 2014-08-07 Icahn School Of Medicine At Mount Sinai Enhanced therapeutic regimens for treating fabry disease
AU2014244167A1 (en) 2013-03-13 2015-10-08 The Children's Hospital Of Philadelphia Adeno-associated virus vectors and methods of use thereof
JP6567494B2 (ja) 2013-03-14 2019-08-28 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ４’−チオ−修飾ヌクレオチドを有するリボ核酸及び関連方法
MX2015012873A (es) 2013-03-15 2016-02-03 Amicus Therapeutics Inc Reticuladores quimicos.
US9447433B2 (en) 2013-03-15 2016-09-20 The University Of North Carolina At Chapel Hill Synthetic adeno-associated virus inverted terminal repeats
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
CN115120746A (zh) 2013-05-15 2022-09-30 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
US20160122727A1 (en) 2013-06-13 2016-05-05 Shire Human Genetic Therapies, Inc. Messenger rna based viral production
US20140377246A1 (en) 2013-06-19 2014-12-25 Carol Ann Foundation and International Morquio Organization Enzyme replacement therapy for treating mps vii related bone lesions using a chemically modified enzyme
RU2664471C2 (ru) 2013-07-26 2018-08-17 Юниверсити Оф Айова Рисерч Фаундейшн Способы и композиции для лечения болезней мозга
HUE047329T2 (hu) 2013-08-13 2020-04-28 Univ Northwestern Peptiddel konjugált részecskék
TWI793159B (zh) 2013-10-23 2023-02-21 美商健臻公司 重組醣蛋白及其用途
WO2015060722A1 (en) 2013-10-24 2015-04-30 Uniqure Ip B.V. Aav-5 pseudotyped vector for gene therapy for neurological diseases
ES2821882T3 (es) 2013-11-15 2021-04-28 Univ Pennsylvania Composiciones para la supresión de la formación de inhibidores contra el factor VIII en pacientes con hemofilia A.
PL3079695T3 (pl) 2013-12-11 2021-09-27 Genzyme Corporation Inhibitory syntazy glukozyloceramidu
PT3086784T (pt) 2013-12-23 2019-06-27 Bcn Peptides Sa Análogos de bicalutamida ou (s)-bicalutamida como compostos ativadores de exocitose para utilização no tratamento de um distúrbio de armazenamento lisossómico ou glicogenose
CA2938577A1 (en) 2014-02-04 2015-08-13 New York University Progranulin (pgrn) and its derivatives for diagnosis and treatment of lysosomal storage diseases
PT3137497T (pt) 2014-05-02 2021-07-12 Genzyme Corp Vetores de aav para terapia genética na retina e snc
JP6652334B2 (ja) 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
CN106714826A (zh) 2014-09-07 2017-05-24 西莱克塔生物科技公司 用于减弱基因表达调节抗病毒转移载体免疫应答的方法和组合物
WO2016077356A2 (en) 2014-11-10 2016-05-19 Synageva Biopharma Corp. Therapeutic compositions of alpha-l-iduronidase, iduronate-2-sulfatase, and alpha-galactosidase a and methods of use thereof
TW201632626A (zh) 2014-11-21 2016-09-16 臺北榮民總醫院 製備誘導性多功能幹細胞之方法
EP4023755B1 (en) 2014-12-12 2023-04-26 CureVac SE Artificial nucleic acid molecules for improved protein expression
US10889834B2 (en) 2014-12-15 2021-01-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing targeted transgene integration
LT3237621T (lt) 2014-12-22 2023-09-25 Codexis, Inc. Žmogaus alfa-galaktozidazės variantai
AU2015373404B2 (en) 2014-12-30 2021-09-09 CureVac SE Artificial nucleic acid molecules
EP3245220B1 (en) 2015-01-14 2023-09-20 The University of North Carolina at Chapel Hill Methods and compositions for targeted gene transfer
EP3247808B1 (en) 2015-01-21 2021-05-05 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
LT3256594T (lt) 2015-02-10 2022-02-10 Genzyme Corporation Patobulintas virusinių dalelių tiekimas į dryžuotąjį kūną ir smegenų žievę
WO2016134338A1 (en) 2015-02-19 2016-08-25 University Of Florida Research Foundation, Inc. Recombinant aav vectors for gene therapy of human hematopoietic disorders
KR20170116159A (ko) 2015-02-19 2017-10-18 다니스코 유에스 인크. 향상된 단백질 발현
DK3271453T3 (da) 2015-03-17 2021-11-15 eleva GmbH Glycosylerede lysosomale proteiner, fremgangsmåde til fremstilling og anvendelser
CA2979065A1 (en) 2015-03-24 2016-09-29 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
WO2016154313A1 (en) 2015-03-24 2016-09-29 Zywie, Llc High drug loading liquid oral pharmaceutical compositions
US9981021B1 (en) 2015-04-09 2018-05-29 Kinetiq, Inc. Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
EP4491733A3 (en) 2015-04-23 2025-03-26 University of Massachusetts Modulation of aav vector transgene expression
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
MX2017014443A (es) 2015-05-15 2018-08-01 Univ Minnesota Adeno-asociado para administracion terapeutica al sistema nervioso central.
EP3303377B1 (en) 2015-06-05 2022-11-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for transient gene therapy with enhanced stability
EP3317416A4 (en) 2015-07-01 2018-12-26 The Regents of The University of California Retroviral vectors containing a reverse orientation human ubiquitin c promoter
WO2017024137A1 (en) 2015-08-04 2017-02-09 New York University Progranulin (pgrn) fragments and derivatives for treatment or alleviation of lysosomal storage diseases
US20170051267A1 (en) 2015-08-20 2017-02-23 Research Foundation Of The City University Of New York Novel alpha-galactosidase a derivatives
WO2017049161A1 (en) 2015-09-18 2017-03-23 Duke University ACID ALPHA-GLUCOSIDASE AND A β-2 AGONIST FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDER
PT4074331T (pt) 2015-12-08 2025-11-04 Regeneron Pharmaceuticals Inc Composições e métodos para a internalização de enzimas
CA3008013A1 (en) 2015-12-14 2017-06-22 The University Of North Carolina At Chapel Hill Modified capsid proteins for enhanced delivery of parvovirus vectors
GB201522243D0 (en) 2015-12-16 2016-01-27 Ucl Business Plc Treatment
JP6993339B2 (ja) 2015-12-23 2022-02-21 ダニスコ・ユーエス・インク タンパク質産生の強化およびその方法
JP6904959B2 (ja) 2016-01-04 2021-07-21 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド 結合エピトープを含有する融合タンパク質を封入する粒子
EP3402531A4 (en) 2016-01-11 2019-08-14 Medgenics Medical Israel Ltd COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
AR107483A1 (es) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
WO2017136202A1 (en) 2016-02-05 2017-08-10 Emory University Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid
US20180126003A1 (en) 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein

Also Published As

Publication number Publication date
CA2985935A1 (en) 2016-11-17
US12370268B2 (en) 2025-07-29
US11103596B2 (en) 2021-08-31
DK3244931T3 (en) 2019-02-11
EP3244931A1 (en) 2017-11-22
US20220016263A1 (en) 2022-01-20
ES2703814T3 (es) 2019-03-12
KR20180012772A (ko) 2018-02-06
AU2016261453B2 (en) 2019-03-28
CA2985935C (en) 2022-03-22
LT3244931T (lt) 2019-02-11
CN107980063A (zh) 2018-05-01
PL3244931T3 (pl) 2019-04-30
US20180110878A1 (en) 2018-04-26
EP3470088A1 (en) 2019-04-17
TW201706412A (zh) 2017-02-16
WO2016181122A1 (en) 2016-11-17
JP6688812B2 (ja) 2020-04-28
PT3244931T (pt) 2019-01-21
GB201508025D0 (en) 2015-06-24
JP2018520646A (ja) 2018-08-02
AU2016261453C1 (en) 2019-09-12
EP3244931B1 (en) 2018-10-24
CN107980063B (zh) 2021-12-10
HRP20190165T1 (hr) 2019-04-05
AU2016261453A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
TR201820102T4 (tr) Fabri hastalığı gen tedavisi.
Shen et al. Amelioration of alpha-1 antitrypsin deficiency diseases with genome editing in transgenic mice
Argirò et al. Gene therapy for heart failure and cardiomyopathies
AU2015266841C1 (en) Humanized dipeptidyl peptidase IV (DPP4) animals
KR20160026841A (ko) 스터퍼/필러 폴리누클레오티드 서열을 포함하는 벡터 및 사용 방법
Bengtsson et al. Dystrophin gene-editing stability is dependent on dystrophin levels in skeletal but not cardiac muscles
TW201903152A (zh) 高活性調控元件
JP7600124B2 (ja) ポリヌクレオチド
US20230190958A1 (en) AAV Vector for Disrupting Coagulation Factor-Related Gene on Liver Genome
US20250276093A1 (en) Therapeutic adeno-associated virus using codon optimized nucleic acid encoding factor viii
Bengtsson et al. Comparison of dystrophin expression following gene editing and gene replacement in an aged preclinical DMD animal model
Sun et al. Knockout and replacement gene surgery to treat rhodopsin-mediated autosomal Dominant Retinitis Pigmentosa
JP2018519250A (ja) 治療薬としてのｓｍａｄ７遺伝子送達
AU2018323473A1 (en) Methods and compositions for treating cone-rod retinal dystrophy
CN120361216A (zh) 射血分数保留的心衰的治疗以及药物筛选
US20250288692A1 (en) Compositions and methods for treating kcnq4-associated hearing loss
US20220389450A1 (en) Vector system
CN119630433A (zh) 基因疗法组合物及其使用方法
US20250161493A1 (en) Compositions and methods for in vivo nuclease-mediated treatment of ornithine transcarbamylase (otc) deficiency
En Identification of a Novel Enhancer to Drive Robust Cardiac Specific Gene Expression
Gómez-Domínguez et al. CRISPR/Cas9-mediated elimination of the LMNA c. 745C> G pathogenic mutation enhances survival and cardiac function in LMNA-associated congenital muscular dystrophy
Tang et al. Gene therapy for hemophilia B in immature mice using ScAAV-DJ/8-LP1-hFIXco vector
Wang et al. The role and mechanism of RLR innate immune signaling pathway in long-term AAV infection
Durbacz et al. Optimized genomic editing of a common Duchenne muscular dystrophy mutation in patient-derived muscle cells and a new humanized mouse model
Zhu et al. Eliminating bacteria backbone of naked DNA enhanced hFIX expression and reduced inflammatory response in mice